Biomarkers for radiation treatment
AssigneeVarian Medical Systems, Inc.
InventorRenate Parry
Life of this patent
Estimating the term…
Abstract
The methods described herein allow for the classification of patients into groups for receiving optimized radiation treatment based on patient specific biomarker signature. The biomarker signature includes markers that have been shown to correlate with TGF-B expression and to be associated with tumor aggressiveness, radioresistance and poor prognosis. The markers play a key role in the epithelial-mesenchymal transition. The methods described herein provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining TGF-B inhibitors with ionizing radiation to treat cancer patients.
Claims20
A method of identifying a subject as a candidate for treatment with ionizing radiation, comprising:
- (a) determining an expression level of two or more biomarkers in a tumor sample from the subject, wherein the one or more biomarkers are selected from the group consisting of CD44, MMP9, ALDH1A1, Vimentin, hyaluman, beta-catenin, MFG-E8 and CD68;
- and
- (b) comparing the expression level of the two or more biomarkers to an expression level in a normal tissue sample;
- wherein an expression level of the two or more biomarkers in the tumor sample that is modified compared to the expression level in the normal tissue sample identifies the subject as a candidate for treatment with ionizing radiation.
A method for selecting a treatment for a subject having a tumor, comprising:
- (a) determining an expression level of two or more biomarkers in a tumor sample from the subject, wherein the two or more biomarkers are selected from the group consisting of CD44, MMP9, ALDH1A1, Vimentin, hyaluronan, beta-catenin, MFG-E8 and CD68;
- (b) comparing the expression level of the two or more biomarkers to an expression level in a normal tissue sample;
- and
- selecting a treatment if the expression level of the two or more biomarkers is modified compared to the expression level in the normal tissue sample.
A kit comprising reagents capable of detecting expression of a biomarker selected from the group consisting of CD44, MMP9, ALDH1A1, Vimentin, hyaluronan, beta-catenin, MFG-E8 and CD68.
Dependencies are inferred from the claim text.